We are live on ! Find out more

Alpha Tau Medical

DRTS

Market cap $1.33B

14.40 USD

-0.03

0.21%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

14.41

+0.01

0.07%

1 day

-0.21%

5 days

-4.19%

1 month

1.05%

3 months

48.91%

6 months

98.62%

Year to date

198.14%

1 year

274.03%

5 years

20.91%

10 years

20.91%

About: Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Employees: 121

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 11.1%

Neutral 66.7%

Negative 22.2%

Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough

Alpha Tau is positioned for a transformative inflection point with potentially groundbreaking GBM data expected before year-end and pancreatic shortly after. Two out of first three GBM patients achieved a complete response (CR), essentially unheard of in GBM. Alpha Tau is still severely underknown to investors, adding to its re-rating potential.

Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough

Alpha Tau to Participate in September Investor Conferences

JERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd.

Alpha Tau to Participate in September Investor Conferences

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

- IMPACT, a multicenter pilot study of Alpha DaRT ® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total of 48 treated patients, driven by overwhelming demand from patients and clinicians - - Alpha DaRT is delivered as a one-time add-on alongside standard first-line chemotherapy, an approach supported by the favorable safety profile observed in the earlier Israeli and Canadian studies - - With data release targeted for early 2027, IMPACT is intended to inform the design of a planned pivotal study, and anchors a global pancreatic cancer program that also includes the ACAPELLA trial in France and a study at the University of Verona - JERUSALEM, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the completion of patient enrollment in its IMPACT study (Intratumoral Pancreatic Alpha Combination Trial) - a multicenter pilot study evaluating intratumoral Alpha DaRT in combination with first-line chemotherapy for patients with newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma.

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) - - Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting - - Median overall survival of 18.2 months and median progression-free survival of 5.4 months compare favorably with historical benchmarks for pembrolizumab monotherapy in this setting of 12.3 months and 3.2 months, respectively - - No Alpha DaRT-associated serious adverse events were observed; the only two Alpha DaRT-associated adverse events were Grade 1 (mild) - - Results build on foundation of Alpha DaRT monotherapy data in head and neck cancer, and lend support to Alpha Tau's ongoing clinical strategy exploring the combination approach, which the Company continues to discuss with the U.S. FDA - - Trial recruitment is now complete, having met the pre-specified success criterion of its Simon two-stage adaptive design: more than six patients responding to the treatment - JERUSALEM, July 21, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau” or the “Company”) (Nasdaq: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced positive results from a clinical study evaluating Alpha DaRT in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma (HNSCC), in which the combination produced a 100% objective response rate and a median overall survival of 18.2 months among evaluable patients.

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Zacks Investment Research

New Strong Sell Stocks for July 7th

AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.

New Strong Sell Stocks for July 7th

Zacks Investment Research

New Strong Sell Stocks for July 2nd

DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.

New Strong Sell Stocks for July 2nd

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah Medical Center in Israel

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical: A Lot Of Shots On Goal

Alpha Tau Medical (DRTS) is pioneering localized alpha particle radiation for solid tumors, with strong recent clinical and partnership momentum. DRTS's innovative and patented "Alpha DaRT" technology overcomes prior range limitations and shows high response rates in multiple indications. This month's recent Tolmar partnership brings $35M in upfront capital and potential milestones, supporting DRTS's cash runway through 2027 amid ongoing trials.

Alpha Tau Medical: A Lot Of Shots On Goal

See News Rankings

Price charts implemented using Lightweight Charts™